Use of New-to-Market Neurologic Medications Reported to Be Low

Use of most new-to-market meds was <20 percent; costs for these medications were substantially larger

different size of pills
Adobe Stock

WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- Utilization of new-to-market neurologic medications in the privately insured population remains low, according to a study published online Nov. 30 in Neurology.

Evan L. Reynolds, Ph.D., from the University of Michigan in Ann Arbor, and colleagues compared the utilization and costs of new-to-market neurologic medications with existing guideline-supported neurologic medications over time using data from a health care pharmaceutical claims database from 2001 to 2019. Patients with both a diagnosis of one of 11 separate neurologic conditions and either a new-to-market medication or an existing guideline-supported medication for that condition were identified.

The researchers found that compared with existing, guideline-supported medications, utilization of most new-to-market medications was low (<20 percent in all but one condition). For new-to-market medications, the out-of-pocket and standardized total costs were substantially larger. In 2019, the largest median out-of-pocket costs for a 30-day supply were for edaravone ($712.80) and eculizumab ($91.10). The distribution of out-of-pocket costs was highly variable for new-to-market medications, and the trends over time were unpredictable compared with existing guideline-supported medications.

"For new, high-cost medications that have similar effectiveness to older drugs, limited use is likely appropriate," a coauthor said in a statement. "However, future studies are needed to look into whether the high costs are barriers to those new medications that can really make a difference for people living with neurologic disease."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Elana Gotkine

Elana Gotkine

Published on November 30, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ